33 results about "Viremia" patented technology

The present application relates to a virus of reverse genetic operation construction of NADC34-like PRRSV2. Specifically, the full gene sequence of NADC34-like PRRSV2 BJ1805-2 isolated strain is segmented and connected to the vector by using PCR amplification, enzyme digestion and other methods with pACY177 plasmid as the carrier, and the BJ1805-2 full-length infectious clone recombinant plasmid (rBJ1805-2) is obtained. The infectious clone virus rBJ1805-2 is rescued in vitro, and the first NADC34-like PRRSV2 strain infectious clone platform in China is successfully built. The present application also relates to a modification method for constructing NADC34-like PRRSV2 strain which can adapt to Marc-145 cell passage culture. The infectious clone virus constructed by the present application has good in vitro and in vivo proliferation efficiency, and can cause specific viremia after inoculation in pigs; it has good safety, does not cause fever after inoculation in pigs, and will not cause piglet death. The modified strain can be used as a candidate strain for developing the first NADC34-like PRRSV2 specific vaccine in China, and is conducive to the prevention and control of PRRSV epidemic in China.

The invention discloses an application of lactic acid (Lactate) in prevention and treatment of infection of CyHV-2 (Cyprinid Herpesvirus, CyHV-2), SVCV (Spring Viraemia of Carp Virus) and GCRV (Grass Carp Reovirus), a result of a cell line infection model shows that the lactic acid has a significant protection effect on cells infected by CyHV-2, SVCV and GCRV, and the lactic acid has a significant protection effect on cells infected by CyHV-2, SVCV and GCRV. Furthermore, a molecular biology experiment result shows that the transcription level of the virus related genes treated by lactic acid is obviously inhibited. Therefore, the lactic acid can be used as a medicine or an additive for preventing and treating CyHV-2, SVCV and GCRV infection, and has the advantages of low dosage and good protection effect.

This invention discloses an oral vaccine against carp spring viremia virus, its preparation method, and its application. The oral vaccine is constructed by linking a carp spring viremia virus antigen protein and a Yellow River carp defensin protein via a flexible linker to form a fusion protein, which is then expressed in *E. coli* and enriched using a biological vector. The gene sequence encoding this fusion protein includes a truncated fragment of the carp spring viremia virus antigen protein gene (64-1389 bp), a fragment of the Yellow River carp defensin protein gene (70-201 bp without the signal peptide), and a flexible linker fusion gene connecting the two gene fragments. Compared with previously reported anti-SVCV vaccines, the oral vaccine against carp spring viremia virus prepared in this invention does not harm the fish during the entire immunization process, is simple to operate, safe and stable, and has a higher protection rate. Therefore, this oral vaccine provides broad prospects for the prevention and control of carp spring viremia.

The present invention belongs to the technical field of veterinary drug production, and provides a PCV2-SVA bivalent vaccine. The vaccine uses the PCV2 Cap protein with the nuclear localization signal removed and the SVA VP2 protein as antigens. The present invention efficiently expresses soluble PCV2 Cap protein and SVA VP2 protein through the baculovirus system. Due to the immune synergy, compared with commercial vaccines or inactivated vaccines, the PCV2-SVA bivalent vaccine prepared based on recombinant proteins can stimulate higher levels of humoral immunity and cellular immunity. The challenge protection test after immunization shows that the bivalent vaccine can effectively reduce the viremia and the virus content in organs. The bivalent genetic engineering vaccine against PCV2 and SVA developed based on the present invention has commercial development prospects.

This application relates to the field of biomedical detection technology, specifically to a combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients and its application. The combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients includes one or more of the following biomarkers: TAP1, ISG15, CMPK2, GBP4, OTOF, and SIGLEC1. The biomarker combination provided in this application can objectively and quantitatively reflect the activity of viral replication and the strength of the immune response in the patient, thereby achieving accurate assessment of the severity of viremia. This solves the problem in existing technologies that mainly rely on qualitative or semi-quantitative detection of viral nucleic acids and lack assessment methods closely related to the host's pathological state.

The invention discloses application of cortisol in prevention and treatment of infection of cyprinid herpesvirus II (CyHV-2), spring viraemia of carp (SVCV) and grass carp reovirus (GCRV), results of a cell line infection model show that the cortisol can play a significant role in protecting cells infected by the CyHV-2, the SVCV and the GCRV, and the cortisol can play a significant role in preventing and treating the infection of the cyprinid herpesvirus II, the SVCV and the GCRV, so that the cortisol can be used for preventing and treating the infection of the cyprinid herpesvirus II, the SVCV and the GCRV, and the application of the cortisol in the prevention and treatment of the infection of the cyprinid herpesvirus II, the SVCV and the GCRV. Furthermore, a molecular biology experiment result shows that the transcription level of the virus related genes treated by cortisol is obviously inhibited. Therefore, cortisol can be used as a medicine or an additive for preventing and treating CyHV-2, SVCV and GCRV infection, and has the advantages of low dosage and good protection effect.

The invention relates to the technical field of virus gene engineering, in particular to a construction method of a porcine respiratory syndrome virus, which comprises the following steps: taking a PRRSV HEB1 strain genome (GenBankEF112447.1) as a template, modifying the template, cloning the modified genome to a pBAC11 vector, and rescuing a recombinant virus rPRRSV-HA-CMV-mC through in vitro transcription and Marc-145 cell transfection. The recombinant PRRSV strain shows remarkable replication delay and titer reduction, and an attenuated phenotype is formed. The recombinant virus and an ISA206 oil adjuvant are further emulsified to prepare the vaccine, the vaccine shows efficient immunogenicity in piglet immunization, clinical symptoms, viremia and lung pathological injury after PRRSV infection can be remarkably reduced, and the vaccine has the potential of being developed into a safe and effective vaccine.

The invention belongs to the technical field of aquaculture, and relates to a new application of capsaicin, in particular to an application of capsaicin in preparation of drugs and / or feed additives for preventing and treating fish virus infection. The core of the invention lies in that the capsaicin has an obvious protection effect on infection of spring viraemia of carp virus (SVCV), grass carp reovirus (GCRV) and herpesvirus type 2 (CyHV-2), and can obviously inhibit transcription of SVCV, GCRV and CyHV-2 virus genes and expression of virus proteins. The capsaicin-containing feed additive and / or medicine can be used for preventing and treating fish virus diseases, and has the advantages of high protection efficiency and environmental friendliness.

This invention discloses an epitope peptide of the key SRCR5 domain of porcine reproductive and respiratory syndrome virus (PRRSV) CD163, an epitope peptide vaccine, and its applications. The epitope vaccine of this invention exhibits good safety, without safety issues such as virulence reversion, viremia, or recombination with other PRRSV strains. It also demonstrates good immunogenicity; 14 days after secondary immunization, it can induce pigs to produce specific antibodies against the CD163 SRCR5-FP14 epitope with a maximum agglutination titer of 1:16. Immunized pigs can resist challenge from the highly pathogenic PRRSV JAX1 strain. Since all PRRSV subtypes rely on interaction with the CD163 receptor to infect susceptible host cells, and the CD163 molecule is conserved, the epitope vaccine blocking PRRSV infection also provides broad-spectrum protection against multiple subtypes without affecting pig production performance. This novel epitope vaccine has broad potential applications in PRRS prevention and control.

This invention belongs to the field of aquaculture technology and relates to a novel use of capsaicin, particularly its use in the preparation of drugs and / or feed additives for the prevention and treatment of fish viral infections. The core of this invention lies in the significant protective effect of capsaicin against carp spring viremia virus (SVCV), grass carp reovirus (GCRV), and carp herpesvirus type 2 (CyHV-2) infections, effectively inhibiting the transcription of SVCV, GCRV, and CyHV-2 viral genes and the expression of viral proteins. Feed additives and / or drugs containing capsaicin can be used for the prevention and treatment of fish viral diseases, offering advantages such as high protective efficiency and environmental friendliness.

The application relates to the technical field of virus genetic engineering, and particularly relates to a construction method of a porcine respiratory syndrome virus. The construction method is as follows: taking a PRRSV HEB1 strain genome (GenBank EF112447.1) as a template and modifying the same, then cloning the modified genome into a pBAC11 carrier, carrying out in-vitro transcription and transfecting Marc-145 cells, and rescuing a recombinant virus rPRRSV-HA-CMV-mC. The recombinant PRRSV strain shows significant replication delay and titer reduction, forming an attenuated phenotype. Further, the recombinant virus is emulsified with an ISA206 oil adjuvant to prepare a vaccine, which shows high immunogenicity in piglet immunization, can significantly reduce clinical symptoms, viremia and lung pathological damage after PRRSV infection, and has the potential to be developed into a safe and effective vaccine.

The application discloses a chimeric Kunjin virus of tamabi virus prM-E and a preparation method and application thereof. On the basis of a reverse genetic manipulation system of the Kunjin virus KUNV, the KUNV prM / E gene is replaced by the DTMUV prM / E gene to construct a chimeric DTMUV virus infectious clone plasmid with the KUNV as a skeleton, which is named as pUC19-KUNV-DTMUV prM / E. Then, the chimeric tamabi virus prM-E Kunjin virus is obtained through virus rescue, and is named as rKUNV-CHv-prM / E (CHv). Analysis on the virus characteristics shows that the CHv can effectively proliferate in BHK-21 and DEF cells, and the duck embryo virulence is weaker than that of the KUNV and the DTMUV. The animal experiment results show that the CHv only detects obvious virus levels in the brain, and does not produce viremia; the CHv after immunization can produce similar IgG antibody levels to those after immunization of the KUNV and the DTMUV. Therefore, the recombinant virus of the chimeric DTMUV prM / E with the KUNV as a skeleton prepared by the application can induce the duckling to produce sufficient immune protective neutralizing antibody levels, and can be applied to preparation of a duck tamabi virus vaccine.

The application belongs to the technical field of genetic engineering of aquatic animals, and discloses application of fish VDAC2 genes in resisting inflammation reaction induced by aquatic viruses. Experimental data of the application show that the inflammation reaction caused by SVCV can be significantly inhibited by using VDAC2 inhibitor Dids or knocking down VDAC2, and the survival rate of fish after infection with the SVCV virus can be effectively improved, so VDAC2 plays an important role in regulating the inflammation reaction induced by the spring viremia of carp virus. The application provides a new drug target for virus prevention and control in the field of aquatic products, and has important significance for prevention and control of aquatic viruses.

The application provides an application of hepatocyte nuclear factor HNF4beta in preparation of a fish disease preventing and / or treating fish biological product, and belongs to the technical field of biotechnology. Through in-vivo experiments, it is found that overexpression of hepatocyte nuclear factor HNF4beta in a fish body can effectively prevent and / or inhibit pathogenic bacteria, especially Edwardsiella tarda, spring viremia of carp virus (SVCV) and grass carp reovirus (GCRV). Meanwhile, the hepatocyte nuclear factor HNF4beta can effectively regulate the immune system, control the occurrence of hepatobiliary syndrome and significantly improve the survival rate of juvenile fish. In addition, the application first proves that HNF4beta can effectively control the hepatobiliary syndrome induced by GCRV infection. The application provides a molecular target for prevention and control of infectious diseases, metabolic diseases and metabolic disease-induced infectious diseases of the Cyprinidae family.

The present disclosure provides a novel serological method for detecting viremia or a latent human-livestock co-occurrence virus infection (e.g., porcine cytomegalovirus (PCMV) or porcine lymphotropic herpesvirus (PLHV) infection) in a subject at any stage of development. More specifically, the present disclosure provides automated multiplex immunoassays for the rapid and simultaneous detection of one or more anti-PCMV or anti-PLHV antibodies in a biological fluid of a subject suspected of being infected with PCMV or PLHV.

The invention discloses a porcine reproductive and respiratory syndrome virus CD163 key SRCR5 structural domain epitope peptide, an epitope peptide vaccine and application. The epitope vaccine is good in safety, has no safety problems of virulence reversion, generation of viremia, recombination with other PRRSV strains and the like, has good immunogenicity, and can induce a pig to generate a specific antibody aiming at the CD163 SRCR5-FP14 epitope with the highest agglutination titer of 1: 16 14 days after secondary immunization, and the immunized pig can resist attack of a highly pathogenic PRRSV JAX1 strain. Each subtype strain of the PRRSV is dependent on interaction with a CD163 receptor so as to infect a host susceptible cell, and CD163 molecules are conservative, so that the epitope vaccine for blocking PRRSV infection also has a broad-spectrum protection effect on various subtype strains, the production performance of pigs is not influenced, and the novel epitope vaccine has a wide potential application prospect in PRRS prevention and control.

The application discloses a duck Tembusu virus attenuated strain, and a nucleotide sequence of the duck Tembusu virus attenuated strain is shown as SEQ ID NO:1.The duck Tembusu virus attenuated strain can immunize ducklings and make the ducklings produce effective duck Tembusu virus antibodies, the protection rate of the ducklings reaches 100%, meanwhile, the weight growth of the ducklings is not affected, and there is no virus discharge, death and viremia, and the duck Tembusu virus is not detected in main organs of the ducklings.The duck Tembusu virus attenuated strain can also be used as a live vector to embed H5N6 subtype avian influenza virus antigen epitopes, and further construct a live vector vaccine strain, and the live vector vaccine strain can immunize ducklings and effectively reduce the damage of H5N6 subtype avian influenza virus to the ducklings.

The invention provides a double qPCR method, a reagent and a kit for realizing ultra-early diagnosis of African swine fever by jointly detecting nucleic acids of host biomarkers HP and ASFV. According to the present invention, the HP and B646L genes are adopted to establish the dual fluorescence PCR method, the biomarker HP and ASFV nucleic acid detection are innovatively combined for use, the ASFV infection is diagnosed, the potential ASFV early stage infected pigs in the pig farm can be screened, the diagnosis blank period before the occurrence of the viremia after the ASFV infection is filled, and the kit can be used for the diagnosis of the ASFV early stage. Especially, a new technical tool is provided for coping with challenges of African swine fever virus variation and recombinant strains. According to the method, the efficiency of biological safety measures can be improved, the implementation precision of a'detection-killing 'strategy is optimized, the method is suitable for precise removal when ASF epidemic outbreak occurs in a pig farm or ASF epidemic outbreak occurs in the periphery, and an early monitoring and early warning means is provided for epidemic prevention and control.

The present invention relates to a vesicular stomatitis virus vaccine vector encoding a MARV glycoprotein (rVSVΔG-MARV-GP). Vaccination with as little as 200 plaque-forming units was 100% efficacious against MARV lethality and prevented development of viremia. rVSVΔG-MARV-GP vaccination induced MARV GP-specific serum IgG, and virus-neutralizing activity in serum was detectable in animals vaccinated with the highest doses.

The invention discloses bacillus coagulans and application thereof, and belongs to the technical field of microorganisms. The bacillus coagulans is preserved in the China Center for Type Culture Collection (CCTCC), the preservation number of the bacillus coagulans is CCTCC NO: M 20251025, and the bacillus coagulans is classified and named as bacillus coagulans WH20. According to the invention, a strain of bacillus coagulans WH20 is separated for the first time, and the strain WH20 can effectively relieve the inflammatory response of aquatic animals after being infected by oxygen deficiency and / or spring viraemia of carp virus (SVCV) and remarkably improve the survival rate of the aquatic animals after being infected by oxygen deficiency and / or spring viraemia of carp virus (SVCV), so that the bacillus coagulans WH20 can be used for preventing and treating the aquatic animals after being infected by oxygen deficiency and / or spring viraemia of carp virus (SVCV). The compound can be developed as a medicine and / or a feed additive for improving the hypoxia resistance and the aquatic virus infection resistance of aquatic animals, and plays an important role in aquaculture.

The invention belongs to the technical field of aquaculture and aquaculture prevention and control, and particularly relates to a composition for RAA-CRISPR / Cas12a integrated detection of spring viremia of carp virus and application. The composition for RAA-CRISPR / Cas12a integrated detection of the spring viraemia of the carp comprises a crRNA sequence for detecting the spring viraemia of the carp and an RAA primer pair for cDNA amplification of the spring viraemia of the carp, the crRNA sequence is shown as any one of SEQ ID NO.9 to SEQ ID NO.13, and the RAA primer pair is shown as any one of SEQ ID NO.1 to SEQ ID NO.8. The invention further discloses a kit for detecting the spring viraemia of the carp. According to the present invention, the integrated reaction of the RAA amplification and the CRISPR / Cas12a detection of the spring viremia of carp virus is achieved, the experiment operation process is simplified, the detection efficiency is improved, the problem that the samples are easily polluted by the step-by-step RAA-CRISPR detection method is effectively overcome, the method is suitable for the fluorescence detection method or the test strip detection method, and the application prospect is wide.

The invention belongs to the technical field of molecular biology and microbiology, and particularly relates to an antibacterial peptide for resisting spring viremia of carp virus and application thereof, and the antibacterial peptide is any one of the following: 1) an amino acid sequence as shown in SEQ ID NO.1; and 2) a nucleotide sequence for coding the amino acid sequence as shown in SEQ ID NO. 1. The invention reveals that the antibacterial peptide NKLj27 has remarkable anti-SVCV activity for the first time, can effectively inhibit infection of SVCV on EPC cells at the cellular level, and alleviates cytopathy and plaque formation caused by viruses. Meanwhile, the NKLj27 shows a good protection effect on SVCV infection at a carp living body level, the death rate caused by virus infection can be remarkably reduced, and the evidences show that the NKLj27 has remarkable anti-SVCV activity. The invention provides a new candidate drug for prevention and control of fish virus diseases.

The invention relates to the technical field of medical biological detection, provides a novel application of HBV RNA, particularly relates to an application in preparation of an LLV screening kit, and further provides a kit and a detection method for performing LLV screening by quantitative detection of HBV RNA. HBV RNA can reflect cccDNA in the liver of a chronic hepatitis B patient and the level of transcriptional activity of cccDNA. In disease assessment and follow-up visit of chronic hepatitis B patients, as a non-invasive assessment means, serum HBV RNA level dynamic monitoring is helpful for early recognition of potential LLV patients, so that the patients are intervened as soon as possible and disease progression is prevented in clinical diagnosis and treatment of chronic hepatitis B.

The present invention belongs to the field of new drugs and specifically relates to a 4H-benzo[b]pyran derivative B95, a preparation method, and its use in combating carp spring viremia virus. Antiviral activity experiments of the 4H-benzo[b]pyran derivative B95 provided by the present invention revealed that the structural compound has a high anti-carp spring viremia virus activity and has minimal toxicity to normal cells. B95 is a new compound with minimal side effects that can combat carp spring viremia virus.

The application belongs to the field of intelligent medical treatment, and particularly relates to a method and device for predicting a BK virus infection disease stage based on gene expression. The method comprises the following steps: obtaining a tissue sample of a to-be-tested person; obtaining an expression amount of a target gene of a region of interest based on the tissue sample, the region of interest being PanCK+, and the target gene comprising one or more of the following: HLA-DPA1 and LYZ; inputting the expression amount of the target gene of the region of interest into a classifier, and predicting a BK virus infection stage of the to-be-tested person according to an output of the classifier, wherein the BK virus infection stage comprises the following: non-infection, BK viremia, and BK nephropathy. The application realizes the differentiation of BK virus infection stages based on gene expression, and helps to realize symptomatic treatment from the gene expression level.

The invention discloses a medicine for preventing and treating spring viremia virus infection of carp, and relates to the field of aquaculture antiviral medicines, and the medicine comprises berberine hydrochloride. Commercial berberine hydrochloride is used as a medicine for inhibiting spring viraemia virus infection of carp, the inhibiting effect is strong, the virus inhibiting rate is high, the safety is high, the application prospect is wide, and the berberine hydrochloride can be prepared into oral preparations for aquatic products.

The application discloses application of deoxycholic acid in preparation of a medicine or additive for resisting aquatic virus infection, wherein the aquatic virus is a spring viremia of carp virus and / or infectious hematopoietic necrosis virus. Experimental data show that the deoxycholic acid can significantly inhibit the proliferation of the spring viremia of carp virus and the infectious hematopoietic necrosis virus in vivo and in vitro, and effectively improve the survival rate of fish after being infected with the two viruses, so that the deoxycholic acid can be developed as a medicine and a feed additive for preventing and controlling viruses in the field of aquaculture, and has important significance for preventing and controlling aquatic viruses.

Lassa fever is a zoonotic viral hemorrhagic disease caused by Lassa virus (LASV), endemic in multiple west African countries where the multimammate rat is a main virus reservoir. The broad geographic range of the rodent host places a large population at risk of serious illness. LASV is also a bioterrorism threat. A LASV vaccine is an unmet need. Applicants advance a vaccine based on a live vesicular stomatitis virus vector for immunizing against the LASV surface glycoprotein. Preclinical evaluation exhibited high efficacy in cynomolgus macaques. The animals developed serum antibodies that could mediate antiviral effector functions including direct neutralization of virus infectivity. This vaccine candidate elicited robust protective immunity in cynomolgus macaques that prevented development of detectable viremia and disease for at least 1 year after vaccination. These protective immune response features provide valuable data for comparison to an ongoing phase 1 clinical trial and planned phase 2b / 3 clinical trials.

The present invention relates to a vesicular stomatitis virus vaccine vector encoding a MARV glycoprotein (rVSVAG-MARV-GP). Vaccination with as little as 200 plaque-forming units was 100% efficacious against MARV lethality and prevented development of viremia. rVSVAG-MARV-GP vaccination induced MARV GP-specific serum IgG, and virus-neutralizing activity in serum was detectable in animals vaccinated with the highest doses. Vaccination may occur via intramuscular administration, oral administration, or intranasal administration.

The present application relates to aquatic animal antiviral technology field, especially to a kind of anti-carp edema virus protein of brocade carp and its application.The amino acid sequence of the anti-carp edema virus protein provided in the present application is shown as SEQ ID NO.1, and the 1-27th amino acid of the amino acid sequence is signal peptide.The nucleotide sequence of the brocade carp Viperin gene for encoding the anti-carp edema virus protein is shown as SEQ ID NO.2.Injection of the Viperin recombinant protein obtained in the present application can improve the immune gene expression of brocade carp infected with carp edema virus.Moreover, after injection of the Viperin recombinant protein obtained in the present application, the content of carp edema virus in gill tissue of brocade carp is significantly lower than that of the control group, and the anti-carp edema virus protein provided in the present application has a significant inhibitory effect on brocade carp infected with carp edema virus.